From hypertension to heart failure -- are there better primary prevention strategies? (Q36643663)

15 August 2017

1 reference

title

From hypertension to heart failure -- are there better primary prevention strategies? (English)

1 reference

15 August 2017

1 reference

Peter A Meredith

1

1 reference

15 August 2017

Jan Ostergren

series ordinal

2

1 reference

15 August 2017

language of work or name

1 reference

1 June 2006

1 reference

Journal of the Renin-Angiotensin-Aldosterone System

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

64-73

1 reference

Mortality by cause for eight regions of the world: Global Burden of Disease Study

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

The Natural History of Congestive Heart Failure: The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Lifetime Risk for Developing Congestive Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

The progression from hypertension to congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Hypertension: an important precursor of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Pathologic hypertrophy with fibrosis: the structural basis for myocardial failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Blood pressure and cardiovascular disease in the Asia Pacific region

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Antecedent hypertension and heart failure after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Blood pressure, stroke, and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid?

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Detection and control of high blood pressure in the community : Do we need a wake-up call?

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

High remaining risk in poorly treated hypertension: the ‘rule of halves’ still exists

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

A population-based European cohort study of persistence in newly diagnosed hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Regression of left ventricular hypertrophy in human hypertension with irbesartan.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Impact of atrial fibrillation on the risk of death: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Epidemiology of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Heart failure in the general population of men--morbidity, risk factors and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Heart failure: the frequent, forgotten, and often fatal complication of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

New-onset diabetes and antihypertensive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2006.012

21 January 2018

Identifiers

DOI

10.3317/JRAAS.2006.012

1 reference

15 August 2017

1 reference